Horizon Therapeutics PLC (NASDAQ:HZNP)

91.47
Delayed Data
As of Apr 09
 +0.47 / +0.52%
Today’s Change
30.00
Today|||52-Week Range
96.54
+25.04%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$20.5B

Company Description

Horizon Therapeutics Plc is a biopharmaceutical company, which is engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Rheumatology, and Inflammation segments. The Orphan and Rheumatology segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises of medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland.

Contact Information

Horizon Therapeutics Plc
Connaught House
Dublin Dublin 4
P:(531) 772-2100
Investor Relations:

Employees

Shareholders

Mutual fund holders47.46%
Other institutional43.29%
Individual stakeholders1.22%

Top Executives

Timothy P. WalbertChairman, President & Chief Executive Officer
Paul W. HoelscherChief Financial Officer & Executive Vice President
Jeffrey W. ShermanChief Medical Officer & Executive Vice President
Jeffrey D. KentExecutive VP-Medical Affairs & Outcomes Research
Karin RosenChief Scientific Officer